 2. MMF will be initiated within the first 1-2 weeks of the start of steroids. Patients will receive CellCept, 750 mg po b.i.d for the first week. Dose will be increased to 1000 mg po b.i.d for the second week, and thereafter, according to blood levels and patient tolerance. Target blood levels are 1 ? 3.5 gml. Treatment will be for a total of 18 months. This is based on the published dose-dependent adverse effect profiles in transplant patients 31-32 and on reports that lower doses are ineffective and shorter courses less then 6 months result in relapses or failure of therapy 25. Dose will be reduced in patient who can not tolerate MMF at the above dose. 